Menu Search
Equities

Recursion Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RXRX:BRN

Recursion Pharmaceuticals Inc

Actions
  • Price (CHF)3.69
  • Today's Change0.00 / 0.00%
  • Shares traded400.00
  • 1 Year change--
  • Beta0.9554
Data delayed at least 15 minutes, as of Jan 16 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

  • Revenue in USD (TTM)43.69m
  • Net income in USD-715.54m
  • Incorporated2013
  • Employees840.00
  • Location
    Recursion Pharmaceuticals Inc41S Rio Grande StreetSALT LAKE CITY 84101United StatesUSA
  • Phone+1 (302) 674-4089
  • Fax+1 (302) 674-5266
  • Websitehttps://www.recursion.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.